Halted: What's going on with Sigma shares today?

Sigma investors would be holding their breath right now.

It's been a great day for the S&P/ASX 200 Index (ASX: XJO) so far this Wednesday. After a rough and wild session yesterday, the ASX 200 seems to be in full recovery mode, which is good news for investors. But not so much for anyone who owns Sigma Healthcare Ltd (ASX: SIG) shares. At least at first glance.

That's because Sigma Healthcare shares are not active on the ASX today. The healthcare stock closed at $3.03 a share yesterday after enjoying a 12.22% boost following the company's latest earnings report.

As we covered at the time, this was a very impressive update. Sigma informed investors that the unlisted Chemist Warehouse chain delivered a 13% rise in total sales to a record high of $5.15 billion over the first half of the 2025 financial year. Sigma is, of course, barrelling towards a full merger with Chemist Warehouse.

Even more luminous were Chemist Warehouse's profits. Sigma revealed that the pharmacy chain boosted its net profits before tax by a whopping 36.1% to $436.8 million.

It therefore wasn't too shocking to see investors push up the Sigma share price so enthusiastically yesterday.

But today, those shares are frozen at $3.03 each, with trading halted.

Man with his hand out the front, symbolising a trading halt.

Image source: Getty Images

Sigma shares halted for crucial Chemist Warehouse merger vote

Yep, this morning, Sigma put out an ASX release just before market open. This release informed investors that Sigma had requested an "immediate implementation of a trading halt". Fortunately, the company provided a detailed explanation as to why this halt was being requested:

The trading halt is requested pending announcements relating to the outcome of the Sigma shareholder meeting and the Chemist Warehouse scheme meeting which will both be held today.

As you know, these meetings relate to the merger between Sigma and Chemist Warehouse, and the passing of certain resolutions at both meetings are conditions precedent to the implementation of the merger.

Sigma requests the trading halt to allow Sigma to manage its continuous disclosure obligations and to ensure that Sigma shares are not trading on an uninformed basis.

Investors have known that this shareholder meeting was to occur today for a while. Sigma's board has already unanimously recommended that shareholders give the deal the green light. That's after the final regulatory approvals were granted late last year. If shareholders vote to proceed with the Chemist Warehouse merger, it will be implemented on 12 February next month.

Given the euphoric response from investors since the merger was first proposed in late 2023, it would be surprising to see it fail this vote. Since December 2023, the Sigma share price has ballooned by roughly 300%, rising from under $1 a share to the $3.03 the company is frozen at today.

Sigma expects its shares to resume trading by tomorrow's session at the latest. At the current share price, the company has a market capitalisation of $4.94 billion.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two scientists analysing results on a computer screen.
Healthcare Shares

$10,000 invested in Pro Medicus and CSL shares 3 years ago is now worth…

Was I better off investing $10,000 into Pro Medicus or CSL shares three years ago?

Read more »

A share market investment manager monitors share price movements on his mobile phone and laptop
Healthcare Shares

Fund managers are loading up on CSL shares. Here's why

CSL is attracting renewed interest from fundies.

Read more »

Happy businessman fist pumping while looking at a tablet.
Healthcare Shares

Mesoblast wins FDA nod for new Ryoncil potency test

Mesoblast gets FDA approval for a new Ryoncil potency assay, aiming to ensure quality and support product expansion.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces.
Healthcare Shares

Can CSL shares hit $200? 3 things that need to go right

CSL needs to prove its earnings engine is accelerating again, not merely stabilising.

Read more »

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »